002581 Shandong Sinobioway Biomedicine
- 11.00
- +1.00+10.00%
Shandong Sinobioway Biomedicine News
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 27% Share Price Plunge Could Signal Some Risk
Shandong Sinobioway Biomedicine (002581.SZ): plans to increase the capital of its wholly-owned subsidiary ShanDong YanDu by 0.29 billion yuan.
On January 3, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced the company is using its own funds to increase capital by 0.29 billion yuan for its wholly-owned subsidiary ShanDong Yandu Biotechnology Co., Ltd. (referred to as "ShanDong Yandu"), of which 0.29 billion yuan will be included in registered capital and 0 yuan in capital surplus. After the capital increase, ShanDong Yandu's registered capital will reach 0.3 billion yuan, remaining a wholly-owned subsidiary of the company. Meanwhile, the Board of Directors has authorized the company's management to handle the specific procedures related to the capital increase.
Shandong Sinobioway Biomedicine (002581.SZ) subsidiary plans to hire Happy Life to provide clinical trial technical services.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's Board of Directors has reviewed and approved the "Agreement on Signing the Technical..."
Shandong Sinobioway Biomedicine (002581.SZ): Granted 19.6346 million stock Options to 100 incentive targets.
On December 23, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced that the granting conditions stipulated in the "2024 Stock Options Incentive Plan (Draft) of Shandong Sinobioway Biomedicine Co., Ltd." have been met. According to the authorization of the fourth extraordinary Shareholders' Meeting of Shandong Sinobioway Biomedicine Co., Ltd. in 2024, the company held the 31st meeting of the 5th Board of Directors and the 21st meeting of the 5th Board of Supervisors on December 20, 2024, to review and approve the "Proposal on Granting Stock Options to the Incentive Objectives of the Company's 2024 Stock Options Incentive Plan," agreeing to use December 2024.
Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years
Shandong Sinobioway Biomedicine (002581.SZ) has appointed Zhou Ting as the financial director.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's board of directors recently received a report from the Chief Financial Officer, Mr. Liu Yangjun...
Shandong Sinobioway Biomedicine (002581.SZ) plans to launch a stock options incentive plan for 2024, with an exercise price of 12.35 yuan per share.
Shandong Sinobioway Biomedicine (002581.SZ) has announced the 2024 stock options incentive plan (draft), which grants...
We're Not Very Worried About Shandong Sinobioway Biomedicine's (SZSE:002581) Cash Burn Rate
Unnamed Pharmaceuticals: Report for the third quarter of 2024
Shandong Sinobioway Biomedicine (002581.SZ): The net income in the first three quarters was 14.6263 million yuan, a year-on-year decrease of 50.78%.
Glory Run on October 29丨Shandong Sinobioway Biomedicine (002581.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.315 billion yuan in the first three quarters, a 6.99% year-on-year decrease; net income attributable to shareholders of the listed company was 14.6263 million yuan, a 50.78% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 16.5706 million yuan, a 49.02% year-on-year decrease; and basic earnings per share was 0.0222 yuan.
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 43% Share Price Surge Not Quite Adding Up
Unnamed Pharmaceuticals: 2024 Semi-Annual Report Summary
Unnamed Pharmaceuticals: Semi-Annual Report 2024
Shandong Sinobioway Biomedicine (002581.SZ) released its half-year performance, with a net loss of 29.6149 million yuan, narrowing by 44.91% year-on-year.
Shandong Sinobioway Biomedicine (002581.SZ) released its 2024 semi-annual report, with revenue of 0.21 billion yuan, a year-on-year increase...
Shandong Sinobioway Biomedicine (002581.SZ): Net loss of 296.149 million yuan in the first half of the year, with a narrowing loss compared to the same period last year.
Shandong Sinobioway Biomedicine (002581.SZ) announced its interim report for the first half of 2024, with a reported revenue of 0.211 billion yuan, a year-on-year increase of 0.77%; a net loss attributable to shareholders of the listed company of -29.6149 million yuan, with a narrower year-on-year loss; a non-recurring profit and loss deducted net profit attributable to shareholders of the listed company of -26.9934 million yuan; basic earnings per share of -0.0449 yuan.
The One-year Earnings Decline Has Likely Contributed ToShandong Sinobioway Biomedicine's (SZSE:002581) Shareholders Losses of 48% Over That Period
Shandong Sinobioway Biomedicine (002581.SZ) plans to transfer 26.838% stake in Yingkou Chemical for a listing price of 98.0468 million yuan.
On August 1st, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) plans to sell 26.8380% equity of Yingkou Yingsheng Chemical Technology Co., Ltd. (hereinafter referred to as “Yingkou Chemical”), held by its wholly-owned subsidiary Shandong Wei Ming Tian Yuan Biotechnology Co., Ltd. (hereinafter referred to as "Wei Ming Tian Yuan"), through public listing on the Shandong Property Rights Trading Center, to further optimize resource allocation, improve asset quality, and increase operational efficiency. The first-time public listing transfer price will not be lower than the assessment value of the target assets by the asset appraisal institution. This equity transfer is planned because the participating company's equity is to be transferred.
Shandong Sinobioway Biomedicine: 2024 Interim Performance Forecast
Shandong Sinobioway Biomedicine (002581.SZ): expected pre-loss of 23 million yuan to 42 million yuan in the first half of the year.
On July 12th, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced its performance forecast for the first half of 2024, with a net loss of 23-42 million yuan attributable to shareholders of listed companies, compared with a loss of 53.7573 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is 20.4-39.4 million yuan, compared with a loss of 48.1417 million yuan in the same period last year; the basic earnings per share were a loss of 0.0349 yuan/share to 0.0637 yuan/share. The reason for the company's loss during the reporting period was due to the decrease in the investment income of the company, and the company will further carry out a new round of global strategic development.
Some Confidence Is Lacking In Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) P/S
No Data
